Source - LSE Regulatory
RNS Number : 0094M
RUA Life Sciences PLC
19 May 2022

19 May 2022


RUA Life Sciences Plc


("RUA Life Sciences", the "Company" or the "Group")

Appointment of Nominated Adviser and Sole Broker

RUA Life Sciences, the holding company of a group of medical device businesses focused on the exploitation of the patented long-term implantable biostable polymer, announces it has appointed Cenkos Securities plc as the Company's nominated adviser and sole broker with immediate effect.


Cenkos Securities plc has been the Company's joint broker since December 2020.



For further information contact:


RUA Life Sciences plc

Bill Brown, Chairman                                                                                               Tel: +44 (0) 77 3071 8296

Caroline Stretton, Group Managing Director                                                      Tel: +44 (0) 7789 901269


Cenkos Securities plc (Nominated Adviser and Broker)                                   Tel: +44 (0) 20 7397 8900

Giles Balleny/Max Gould (Corporate Finance)

Michael Johnson (Sales)



About RUA Life Sciences

The RUA Life Sciences group was created in April 2020 when RUA Life Sciences Plc (formerly known as AorTech International Plc) acquired RUA Medical Devices Limited to create a fully formed medical device business. RUA Life Sciences is the holding company of the Group's four trading businesses, each exploiting the Group's patented polymer technology.

Our vision is to improve the lives of millions of patients by improving and enabling medical devices with Elast-EonTM, the world's leading long-term implantable polyurethane.

Whether it is licensing Elast-EonTM, manufacturing a device or component or developing next generation medical devices, a RUA Life Sciences business is pursuing our vision.


Elast-Eon™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. With over 8 million implants and over 15 years of successful clinical use, RUA's polymers are proven in long-term life enabling applications.


The Group's four business units are:

RUA Medical:

End-to-end contract developer and manufacturer of medical devices and implantable fabric specialist.

RUA Biomaterials:

Licensor of Elast-EonTM polymers to the medical device industry.

RUA Vascular:

Commercialisation of open surgical vascular grafts and patches


RUA Structural Heart:

Development of polymeric leaflet systems for heart valves.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Rua Life Sciences PLC (RUA)

-0.50p (-4.35%)
delayed 15:57PM